Display Settings:

Format

Send to:

Choose Destination

    Clin Chim Acta. 2009 Aug;406(1-2):94-7. Epub 2009 Jun 8.

    Calcium-sensing receptor autoantibodies in primary hyperparathyroidism.

    Charrié A, Chikh K, Peix JL, Berger N, Decaussin M, Veber S, Bienvenu J, Lifante JC, Fabien N.

    University of Lyon, F-69002 Lyon, France.

    BACKGROUND: Mutations in the extracellular calcium-sensing receptor (CaSR) gene are known to be implicated in some cases of primary hyperparathyroidism. However, not all patients display such mutations and so the mechanisms of primary hyperparathyroidism are still largely unknown. An autoimmune origin has been suggested, as autoantibodies against the CaSR have been detected in some patients. The aim of our study was to investigate the presence of CaSR autoantibodies in a large cohort of patients with primary hyperparathyroidism. METHODS: Seventy-five patients were tested for the presence of anti-parathyroid antibodies using an immunoblotting assay with the recombinant extracellular domain of the human CaSR and an immunofluorescence technique with parathyroid adenoma. RESULTS: Five of 75 (6.7%) patients had CaSR autoantibodies. There was no statistically significant difference in the decrease of parathyroid hormone (PTH) level after surgery between patients with or without autoantibodies. Histological examination of parathyroid tissue did not show greater lymphocytic infiltration in patients with autoantibodies than in those without. CONCLUSIONS: This study confirmed that some patients with primary hyperparathyroidism displayed CaSR autoantibodies. The pathophysiological role of these autoantibodies in hyperparathyroidism needs to be further elucidated.

    PMID: 19520070 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read